| Literature DB >> 21969806 |
Edavan P Praveen1, Jaya Prakash Sahoo, Bindu Kulshreshtha, Madan L Khurana, Nandita Gupta, Sada Nand Dwivedi, Guresh Kumar, Ariachery C Ammini.
Abstract
BACKGROUND: There is no consensus on the role of cortisol in the pathogenesis of obesity and metabolic syndrome (MS). This cross-sectional study aimed to analyze the relationship of morning plasma cortisol and adrenocorticotropic hormone (ACTH) levels with body mass index (BMI) and glucose tolerance. SUBJECTS AND METHODS: The sample frame was the "Offspring of individuals with diabetes study" database. A total of 358 offspring of individuals with type 2 diabetes mellitus (T2DM) and 287 individuals without a known family history of T2DM were recruited for the study. Subjects who were ≥10 years of age were selected from the database for analysis. Subjects with T2DM were excluded. All participants underwent a 75 g oral glucose tolerance test (OGTT), and blood samples were collected at 0, 30, 60, and 120 minutes for glucose, insulin and C-peptide. Plasma cortisol, ACTH, and lipid profile were estimated from the fasting sample.Entities:
Keywords: ACTH; cortisol; cortisol and body weight; cortisol and glucose tolerance; cortisol and obesity; metabolic syndrome
Year: 2011 PMID: 21969806 PMCID: PMC3180524 DOI: 10.2147/DMSO.S23915
Source DB: PubMed Journal: Diabetes Metab Syndr Obes ISSN: 1178-7007 Impact factor: 3.168
Plasma ACTH and cortisol levels in normal-weight and overweight subjects in different fasting glucose categories
| Glucose 0 min ≤80 mg/dL | Glucose 0 min 80.1–90 mg/dL | Glucose 0 min 90.1–100 mg/dL | Glucose 0 min 100.1–125 mg/dL | |||
|---|---|---|---|---|---|---|
| Unadjusted | Adjusted for age, gender | |||||
| n | 73 | 176 | 97 | 12 | – | – |
| Age (years) | 21.9 ± 7.8 | 24.9 ± 8.0 | 25.9 ± 9.7 | 31.3 ± 10.1 | 0.001 | – |
| BMI (kg/m2) | 20.1 ± 3.2 | 20.6 ± 3.1 | 20.6 ± 2.8 | 22.7 ± 2.0 | 0.04 | 0.500 |
| ACTH (pg/mL) | 20.0 ± 15.5 | 24.5 ± 19.6 | 33.8 ± 26 | 31.0 ± 21 | <0.001 | 0.003 |
| Cortisol (ng/mL) | 10.9 ± 4.4 | 11.3 ± 4.9 | 12.0 ± 5.0 | 14.9 ± 4.7 | 0.050 | 0.163 |
| n | 26 | 55 | 39 | 17 | – | |
| Age (years) | 26.2 ± 10 | 31.7 ± 11 | 30.3 ± 11 | 32.2 ± 11 | 0.20 | – |
| BMI (kg/m2) | 28.1 ± 2.6 | 28.7 ± 3.3 | 29.9 ± 5.0 | 29.6 ± 4.3 | 0.30 | – |
| ACTH (pg/mL) | 16.6 ± 15 | 19.0 ± 19 | 24.3 ± 18 | 23.1 ± 13 | 0.14 | 0.32 |
| Cortisol (ng/mL) | 10.1 ± 4.5 | 10.4 ± 4.6 | 10.7 ± 5.0 | 10.9 ± 4.9 | 0.80 | 0.79 |
| n | 99 | 231 | 136 | 29 | – | |
| Age (years) | 23.0 ± 8.7 | 26.6 ± 9.6 | 27 ± 10.3 | 31.9 ± 10.7 | <0.001 | – |
| BMI (kg/m2) | 22.2 ± 4.7 | 22.6 ± 4.7 | 23.4 ± 5.5 | 26.8 ± 4.9 | <0.001 | – |
| ACTH (pg/mL) | 19.1 ± 15 | 23.2 ± 20 | 31.1 ± 24.5 | 26.3 ± 17 | <0.001 | 0.001 |
| Cortisol (ng/mL) | 10.7 ± 4.4 | 11.1 ± 4.8 | 11.6 ± 5.1 | 12.6 ± 5.2 | 0.236 | 0.434 |
Abbreviations: ACTH, adrenocorticotropic hormone; BMI, body mass index.
Plasma ACTH and cortisol levels in subjects with and without MS in positive and negative family history of T2DM categories
| Subjects with family history of T2DM
| Subjects without family history of T2DM
| |||||
|---|---|---|---|---|---|---|
| MS | No MS | MS | No MS | |||
| n | 50 | 228 | – | 27 | 190 | – |
| Males (%) | 27 (54) | 133 (58) | 0.575 | 19 (70) | 126 (66) | 0.675 |
| Age | 35.2 ± 10.5 | 21.8 ± 8.6 | <0.001 | 34.2 ± 8.2 | 28.3 ± 8.5 | 0.001 |
| BMI | 28.9 ± 4.37 | 22.4 ± 5.3 | <0.001 | 25.4 ± 2.4 | 21.6 ± 3.5 | <0.001 |
| ACTH | 19.7 ± 13.9 | 23.7 ± 20 | 0.211 | 29.0 ± 23 | 26.5 ± 22.2 | 0.840 |
| Cortisol | 9.6 ± 4.2 | 11.1 ± 4.8 | 0.045 | 11.3 ± 4.8 | 11.8 ± 5.0 | 0.423 |
Note: Data adjusted for age and gender.
Abbreviations: ACTH, adrenocorticotropic hormone; BMI, body mass index; MS, metabolic syndrome; T2DM, type 2 diabetes mellitus.
Correlation of morning cortisol with metabolic syndrome-related risk factors in males and females
| Males | Females | |||||||
|---|---|---|---|---|---|---|---|---|
| Adjusted for age
| Adjusted for age and BMI
| Adjusted for age
| Adjusted for age and BMI
| |||||
| WC (cm) | −0.12 | 0.03 | −0.05 | 0.46 | ||||
| Waist to hip ratio | −0.07 | 0.2 | 0.02 | 0.76 | −0.06 | 0.25 | −0.06 | 0.38 |
| Fasting insulin (μIU/mL) | −0.139 | 0.015 | −0.04 | 0.45 | −0.02 | 0.81 | −0.01 | 0.84 |
| Fasting glucose (mg/dL) | −0.003 | 0.95 | 0.02 | 0.71 | 0.15 | 0.04 | 0.15 | 0.03 |
| HOMA-IR (μU/mL, mmol/l) | −0.133 | 0.02 | −0.04 | 0.50 | 0.01 | 0.94 | 0.01 | 0.83 |
| IGI 30 (nmol/mmol) | −0.198 | 0.001 | −0.156 | 0.009 | 0.02 | 0.78 | 0.02 | 0.78 |
| TG (mg/dL) | 0.061 | 0.29 | 0.11 | 0.06 | −0.01 | 0.84 | −0.01 | 0.86 |
| Total cholesterol (mg/dL) | 0.054 | 0.35 | 0.09 | 0.09 | 0.10 | 0.15 | 0.10 | 0.14 |
| HDL-cholesterol (mg/dL) | 0.149 | 0.01 | 0.12 | 0.04 | 0.09 | 0.19 | 0.10 | 0.17 |
| LDL-cholesterol (mg/dL) | −0.012 | 0.82 | 0.02 | 0.71 | 0.09 | 0.21 | 0.09 | 0.21 |
| Systolic BP (mmHg) | −0.04 | 0.52 | 0.01 | 0.76 | 0.15 | 0.05 | 0.15 | 0.04 |
| Diastolic BP (mmHg) | −0.04 | 0.52 | 0.02 | 0.66 | 0.12 | 0.11 | 0.12 | 0.11 |
Note: Significant P < 0.05.
Abbreviations: ACTH, adrenocorticotropic hormone; BMI, body mass index; BP, blood pressure; HOMA-IR, homeostasis model assessment-insulin resistance; IGI 30, insulinogenic index (0−30); HDL-cholesterol, high-density lipoprotein cholesterol; LDL-cholesterol, low-density lipoprotein cholesterol; MS, metabolic syndrome; T2DM, type 2 diabetes mellitus; TG, triglycerides; WC, waist circumference.